VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients
February 07, 2019 08:00 ET
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the study without modificationEnrollment is complete in the high-dose study arm of Part AExpanded immunologic...
National Brain Tumor Society Invests in GBM AGILE, the World’s First Global Adaptive Trial for Glioblastoma Brain Cancer
January 16, 2019 13:56 ET
|
National Brain Tumor Society
Boston, MA, Jan. 16, 2019 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, today announced a partnership...
Incysus Therapeutics Completes Series A Financing and Announces the Appointment of Travis Whitfill, MPH to Its Board of Directors
January 03, 2019 14:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Gamma-Delta (γδ) T Cell Therapy Combined With Checkpoint Inhibition Shows Potential Synergies in Vitro for Treatment of Glioblastoma
November 15, 2018 07:00 ET
|
Incysus Therapeutics, Inc.
Promising data from gamma-delta (γδ) T cell therapy in combination with checkpoint inhibitors to be presented at 2018 Society for Neuro-Oncology annual meeting NEW YORK, Nov. 15, 2018 (GLOBE...
Oblato acquires all rights to glioblastoma drug from OMRF
October 29, 2018 11:21 ET
|
Oklahoma Medical Research Foundation
OKLAHOMA CITY, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Oblato, Inc., has acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of...
VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
October 24, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
NX Development Corp. (NXDC) Launches FDA-Approved Gleolan™ (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas)
October 03, 2018 14:50 ET
|
NX Development Corp.
Lexington, KY, Oct. 03, 2018 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company, today announced the U.S. commercial launch of its flagship product Gleolan™ (aminolevulinic...
VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards
September 26, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
National Brain Tumor Society Statement on Passing of Sen. John McCain
August 27, 2018 14:59 ET
|
National Brain Tumor Society
Boston, MA , Aug. 27, 2018 (GLOBE NEWSWIRE) -- National Brain Tumor Society is profoundly saddened to learn of the senator’s passing, and our thoughts immediately go out to his family, friends,...
VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
April 17, 2018 08:00 ET
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationLow-dose study arm: enrollment completeIntermediate-dose study arm: enrollment...